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The heart, more than any other organ, requires precise functionality on a second-to-second basis throughout
the lifespan of the organism. Even subtle perturbations in cardiac structure or function have catastrophic
consequences, resulting in lethal forms of congenital and adult heart disease. Such intolerance of the heart
to variability necessitates especially robust regulatory mechanisms to govern cardiac gene expression.
Recent studies have revealed central roles for microRNAs (miRNAs) as governors of gene expression during
cardiovascular development and disease. The integration of miRNAs into the genetic circuitry of the heart
provides a rich and robust array of regulatory interactions to control cardiac gene expression. miRNA regu-
latory networks also offer opportunities for therapeutically modulating cardiac function through the manip-
ulation of pathogenic and protective miRNAs. We discuss the roles of miRNAs as regulators of cardiac
form and function, unresolved questions in the field, and issues for the future.Introduction
The heart is the first organ to form and function in the embryo,
and all subsequent events in the life of the organism depend on
its uninterrupted contractility. Heart development is an extraordi-
narily complex process involving the integration of multiple cell
lineages into the 3D organ and its seamless connection to
the vascular system. Abnormalities in heart formation result in
congenital heart disease, the most common human birth defect,
and abnormalities in function of the adult heart result in a spec-
trum of fatal disorders, including arrhythmias, cardiomyopathies,
heart failure, and sudden death (Bruneau, 2008; Olson and
Schneider, 2003).
Heart formation and function are precisely controlled by
networks of transcription factors that link upstream signaling
systemswith the protein-coding genes required for cardiacmyo-
genesis, morphogenesis, and contractility (Olson, 2006). It has
recently become apparent that cardiac signaling and transcrip-
tional pathways are intimately intertwined with a collection of
microRNAs (miRNAs) that act as ‘‘rheostats’’ and ‘‘switches’’
to modulate multiple facets of cardiac development, function,
and disease. The myriad roles of miRNAs in the cardiovascular
system exemplify the power of miRNAs to modulate complex
phenotypes at the cellular and organ levels and highlight many
fascinating, unanswered questions about this new frontier in
biology. Here we review recent studies that illustrate the mecha-
nisms of miRNA action during cardiovascular development and
the important issues for the future.
miRNA Biogenesis and Function
miRNAs are a class of 21–25 nucleotide (nt) noncoding RNAs
that are evolutionarily conserved in metazoans (Bartel, 2004).
There are estimated to be as many as 1000 miRNAs encoded
by the human genome, about half of which have been cloned
and confirmed. Based on their locations in the genome, these
regulatory miRNAs can be classified as intergenic, intronic,
and exonic miRNAs. Intergenic miRNAs are derived from their
own transcriptional units in the intergenic regions of the genome510 Developmental Cell 18, April 20, 2010 ª2010 Elsevier Inc.(Bartel, 2004). Intronic and exonic miRNAs are located within the
introns and exons of host genes (protein-coding or nonprotein
coding genes), respectively, and are usually cotranscribed and
coexpressed with their host genes. A subset of miRNAs are
also encoded within introns, but are transcribed in the opposite
orientation of the host genes and have their own cis-regulatory
elements. Approximately half of all miRNAs are encoded by
polycistronic transcription units that generate multiple miRNAs
(Bartel, 2004).
Most animal miRNAs share common biogenesis and effector
pathways (Bartel, 2004). miRNAs are transcribed by RNA poly-
merase II as precursor molecules called pri-miRNAs, which
can encode single or multiple miRNAs (Cai et al., 2004; Lee
et al., 2004). Pri-miRNAs fold into hairpin structures containing
imperfectly base-paired stems and are processed by the endo-
nuclease Drosha and its cofactor DiGeorge syndrome critical
region 8 (DGCR8) into 60–100 nt hairpins known as pre-miRNAs
(Figure 1) (Denli et al., 2004; Gregory et al., 2004; Lee et al., 2003).
The pre-miRNAs are exported from the nucleus to the cytoplasm
by exportin 5 (Yi et al., 2003), where they are cleaved by the
endonuclease Dicer to yield imperfect miRNA-miRNA* duplexes
(Chendrimada et al., 2005). The miRNA strand is selected to
become a mature miRNA, while most often the miRNA* strand
is degraded. Occasionally, both strands give rise to functional
miRNAs. The mature miRNA is incorporated into the RNA-
induced silencing complex (RISC), which recognizes specific
targets and induces posttranscriptional gene silencing (Khvor-
ova et al., 2003; Schwarz et al., 2003). Several mechanisms
have been proposed for this mode of regulation: miRNAs can
inhibit translational initiation, mark target mRNAs for degradation
by deadenylation, or sequester targets into cytoplasmic P bod-
ies (Filipowicz et al., 2008). In rare cases, animal miRNAs also
lead to mRNA cleavage, similarly to plant miRNAs. While
miRNAs act most commonly to repress their mRNA targets, in
rare cases they have also been reported to stimulate mRNA
translation (Vasudevan et al., 2007); in one case by over 100-fold
(Cordes et al., 2009). Recently, miRNAs have been detected in
Figure 1. MicroRNA Biogenesis
miRNAs are transcribed as long precursors (pri-miRNAs), which are processed
by Drosha and DGCR8 into hairpins called pre-miRs, which are processed
by Dicer and TRBP to form mature miRNAs as a heteroduplex with miRNA*.
miRNAs regulate numerous processes as shown.
Developmental Cell
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cating that miRNAs can be secreted and may mediate intercel-
lular communication (Gibbings et al., 2009; Hunter et al., 2008;
Valadi et al., 2007).
Multiplicity of miRNA Targets
miRNA target identification remains a major challenge. Most
metazoan miRNAs bind to the 30 UTRs of target mRNAs,
although there are also cases in which miRNAs repress mRNA
targets through binding sites in 50 UTRs or coding regions (Kloos-
terman et al., 2004; Lytle et al., 2007). Unlike plant miRNAs that
base pair to mRNAs with nearly perfect complementarity and act
as siRNAs to promote mRNA decay, metazoan miRNAs most
commonly form imperfect base pairs with target sequences.
Therein lies the difficulty in target identification. Nucleotides
2–8 of the miRNA, termed the ‘‘seed’’ sequence, are essential
for target recognition and binding (Bartel, 2009). While pairing
beyond the seed sequence has only modest consequences for
target recognition (Bartel, 2009), in some cases, pairing to the
30 portion of the miRNA can supplement the 50 seed match and
compensate for a single mismatch in the seed region (Vella
et al., 2004) (Yekta et al., 2004). Other variables, such as posi-
tions of miRNA binding sites, site accessibility, RNA secondary
structure, and proximity of sites for other miRNAs and RNA
binding proteins also influence miRNA:mRNA interactions
(Bartel, 2009).
miRNAs have numerous high- and low-affinity targets, aver-
aging 300 conserved targets per miRNA family (Bartel, 2009).
Individual 30 UTRs also contain binding sites formultiplemiRNAs,
allowing redundancy and cooperation betweenmiRNAs. In addi-
tion, the proteins encoded by mRNA targets of miRNAs can
themselves modulate the expression of additional miRNAs,increasing the complexity of miRNA-dependent gene regulatory
circuits. It is likely therefore that miRNAs participate in nearly
every physiological process.
Because miRNAs generally exert their effects through rela-
tively subtlemodulation of numerous targets, rather than through
dramatic regulation of single targets, they are often considered
to function as ‘‘fine-tuners’’ that eliminate the expression of
low-level transcripts that are inappropriate for a particular cell
type, thereby providing robustness to cellular phenotypes
(Bartel, 2009). A classic example is the muscle-specific miRNA
miR-1 which, when misexpressed in nonmuscle cells, shifts the
mRNA expression profile toward that of muscle (Lim et al.,
2005). However, there are also settings in which miRNAs func-
tion as ‘‘on-off’’ switches (Reinhart et al., 2000; van Rooij et al.,
2007). In perhaps the clearest example of such regulation
described to date, the cardiac-specific miRNA miR-208 regu-
lates a cohort of transcriptional repressors that synergize to
silence the expression of slow muscle fiber genes (van Rooij
et al., 2007, 2009). In the absence of miR-208, upregulation of
each repressor by roughly 2-fold results in cooperative and virtu-
ally complete inhibition of downstream target genes of these
repressors.
By regulating the expression of multiple proteins that func-
tion at different steps in complex biological pathways, miRNAs
are able to exert powerful effects on cellular processes such
as growth, differentiation, metabolism, and apoptosis (Ambros,
2004; Kloosterman and Plasterk, 2006). Thus, although the
effects of an individual miRNA on a specific mRNA target may
be relatively modest, the combined effects of a miRNA on
multiple targets functioning within a common pathway can be
synergistic. In this respect, miRNAs act in a manner distinct
from that of classical drugs, which are designed to impose
maximal inhibition on single targets. Instead, by modestly inhib-
iting multiple targets with shared functional consequences,
miRNAs are able to circumvent possible redundant mechanisms
that might bypass a single inhibited target.
Validation of miRNA targets and identification of specific tar-
gets responsible for miRNA-dependent phenotypes represent
significant challenges in the field. Current experimental tools
for target validation rely on reporter assays in which 30 UTRs con-
taining the putative miRNA binding site are linked to artificial
reporter genes, and repression by miRNAs is analyzed by
reporter activities in transient overexpression assays. mRNA
and protein levels of putative targets are also analyzed in vitro.
However, because in vitro assays involve transient overexpres-
sion and knockdown of miRNAs, targets validated in vitro may
not represent bona fide targets that respond to physiological
levels of miRNAs in vivo.
In addition to regulating downstream mRNA targets, miRNAs
often operate through feedback loops to ensure precise control
of both their own expression and that of their targets (Figure 2).
In feedforward loops, miRNAs can enhance gene expression
through repressing negative regulators of a pathway, such as
in the case of miR-1 and histone deacetylase 4 (HDAC4) in
muscle cells. Repression of HDAC4 by miR-1 derepresses the
activity of the MEF2 transcription factor, which, in turn, activates
expression of miR-1 and other target genes (Figure 2A) (Chen
et al., 2006). miRNAs can also establish negative feedback
loops by repressing activators of miRNA/mRNA expression.Developmental Cell 18, April 20, 2010 ª2010 Elsevier Inc. 511
Figure 2. miRNA Regulatory Loops
In feedforward regulation (A), miRNAs repress
a repressor, leading to activation of transcrip-
tion factors that activate miRNAs expression.
The regulatory loop formed between miR-1,
HDAC4, andMEF2 exemplifies this form of regula-
tion. In a negative feedback loop (B), miRNAs
repress transcription factors that are required for
miRNA expression, leading to decreased expres-
sion of miRNAs. The regulatory loop formed
between miR-133 and SRF exemplifies this form
of regulation.
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SRF in muscle cells is an example of such a regulatory loop
(Chen et al., 2006; Liu et al., 2008). In this case, SRF regulates
the expression of miR-133, which represses expression of
SRF, providing feedback control to the pathway (Figure 2B).
Especially intriguing is the finding that the actions and expres-
sion of certain miRNAs are modulated under conditions of cell
stress (Leung and Sharp, 2007). This facet of miRNA biology is
of particular importance in diseases of the heart in whichmiRNAs
have been shown to exert protective and pathogenic functions
(Divakaran and Mann, 2008; Latronico and Condorelli, 2009;
van Rooij and Olson, 2007). The precise mechanisms whereby
stress signals potentiate miRNA action have not been fully
defined, but there is evidence for stress-dependent modulation
of miRNA processing and association of miRNAs and mRNA
targets with P bodies, the sites of mRNA repression (Bhattachar-
yya et al., 2006).Requirements of Cardiac miRNAs Revealed
by Dicer Deletion
The consequences of inhibition of miRNA expression have been
examined by deletion of Dicer, the RNase essential for miRNA
biosynthesis. Cardiac deletion of Dicer, using Cre recombinase
under control of cardiac regulatory DNA sequences, results in
lethality at different developmental stages depending on the
temporal expression pattern of theCre transgene. Deletion using
Nkx2.5 regulatory elements, which direct expression in cardiac
progenitor cells by embryonic day (E) 8.5, causes lethality at
E12.5, with hearts displaying pericardial edema and hypoplastic
ventricular myocardium (Zhao et al., 2007). Postnatal deletion of
Dicer in cardiomyocytes using Cre recombinase under control of
the a-myosin heavy chain (MHC) promoter causes dysregulation
of cardiac contractile proteins and sarcomere disarray, resulting
in dilated cardiomyopathy, heart failure, and lethality (Chen et al.,
2008). Similarly, deletion ofDicer in the adult heart using a tamox-
ifen-inducible Cre recombinase causes heart failure and death
(da Costa Martins et al., 2008). While these studies demonstrate
the importance of miRNAs in heart development and function, it
is unclear whether the severe phenotypes resulting from Dicer
deletion reflect requisite roles of specific miRNAs or, more likely,
the collective functions of numerous miRNAs in multiple essen-
tial processes. Pinpointing specific miRNAs that mediate the
actions of Dicer is complicated by the paradoxical finding that
numerous miRNAs are upregulated in hearts of adult mice
following cardiac Dicer deletion, which likely reflects secondary
changes in miRNA expression in noncardiomyocytes within the
heart (da Costa Martins et al., 2008).512 Developmental Cell 18, April 20, 2010 ª2010 Elsevier Inc.The Muscle-Specific miR-1/133 Gene Clusters
miR-1 was the first miRNA to be implicated in heart development
(Zhao et al., 2005) and is the most extensively studied miRNA
in muscle. Nearly identical in sequence in organisms ranging
from fruit flies to humans, miR-1 is expressed specifically in stri-
ated muscle cells in all organisms. In vertebrates, miR-1 and
miR-133 are generated from a common bicistronic transcript
(Figure 3A), whereas these miRNAs are transcribed separately
in invertebrates, suggesting they became genetically linked
during the evolutionary emergence of vertebrates (Chen et al.,
2006). In contrast to the muscle specificity of miR-1, miR-133
is expressed in nonmuscle cell types of invertebrates, indicating
that it became incorporated during evolution into themiR-1 locus
and thereby acquired muscle specificity. The miR-1/133 locus
also duplicated twice to yield three related miRNA clusters (miR-
1-1/133a-2, miR-1-2/133a-1, and miR-206/133b) (Figure 3A).
The former two clusters are expressed in cardiac and skeletal
muscle, whereas the latter cluster is skeletal muscle specific
(Chen et al., 2006; Lagos-Quintana et al., 2002; Rao et al., 2006;
Sempere et al., 2004; Williams et al., 2009; Zhao et al., 2005).
Cardiac- and skeletal-muscle-specific expression of the
miR-1/133a clusters are regulated by upstream and intragenic
enhancers controlled by combinations of the MADS-box tran-
scription factors SRF and MEF2 and the basic helix-loop-helix
(bHLH) protein MyoD (Figure 3B) (Liu et al., 2007; Zhao et al.,
2005). The same transcription factors activate protein-coding
genes involved in muscle function (e.g., sarcomere genes), dem-
onstrating the intimate integration of miRNA and mRNA regula-
tory networks. The existence of multiple independent enhancers
of the miR-1/133 genes allows fine-tuning of temporal-spatial
control of gene expression, and provides a means of reinforcing
their cardiac- and skeletal-muscle-specific expression during
development.
The regulatory connection between SRF/MEF2 and miR-1
was conserved during evolution. In flies, for example, SRF also
regulates the cardiac expression of miR-1, and MEF2 cooper-
ates with the bHLH transcription factor Twist to control expres-
sion in the skeletal musculature (Kwon et al., 2005; Sokol and
Ambros, 2005). Thus, the key transcription factors for myogene-
sis were locked in with muscle-specific miRNAs to establish an
integrated transcriptional-miRNA regulatory network that con-
trols fundamental aspects of myogenesis.
The remarkable evolutionary conservation of miR-1 and miR-
133 sequences raises interesting questions about the mecha-
nism of action of these miRNAs and the basis for the apparent
selection pressure to maintain their sequences across vast
evolutionary distances. If the primary determinant of mRNA tar-
get recognition is the seed sequence and variability is tolerated
Figure 3. Genomic Organization and Transcriptional Regulation of the miR-1/miR-133 Cluster
(A) Bicistronic miR-1/miR-133 clusters and the muscle tissues in which they are expressed are shown.
(B) Transcriptional regulation ofmiR-1/miR-133a genes in heart and skeletal muscle. The upstream and intragenic enhancers of each locus, and the transcription
factors that act on these cis-regulatory elements, are shown. The expression patterns of lacZ transgenes controlled by the intragenic enhancers of each locus are
shown in mouse embryos at E11.5. The bottom panel shows expression patterns of these enhancers in transverse sections of the hearts.
a, atrium; lv, left ventricle; rv, right venticle. Embryo images are from Liu et al., 2007.
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across their entire lengths? Most likely, conserved nucleotides
outside the seed play important roles in aspects of miRNA
biogenesis or functions independent of mRNA recognition
(e.g., interactions with accessory factors or other regulatory
components), or perhaps these nucleotides mediate com-
pletely different functions (e.g., transcriptional control). It is
also intriguing that these miRNAs are so conserved both in their
sequence and their muscle-specific expression while their
mRNA targets are not evolutionarily conserved. The divergence
of mRNA targets suggests that the regulatory circuits controlled
by these miRNAs are relatively plastic and acquired or lostduring evolution, whereas there must be strong evolutionary
pressure to maintain the precise sequences of these miRNAs.
Alternatively, over the course of evolution, mRNAs that are
crucial for essential cellular functions are likely under selective
pressure to avoid being repressed by miRNAs, by either (1)
changing the cell types where targets are expressed so that
targets and miRNAs are not present in the same tissue, or (2)
by harboring mutations in the 30 UTRs so that recognition by
seed sequences is dampened (Bartel, 2009). Therefore, in
some cases, nonconserved targets may represent important
species-specific repression, which may be critical for the func-
tions of miRNAs.Developmental Cell 18, April 20, 2010 ª2010 Elsevier Inc. 513
Figure 4. Functions ofmiR-1 andmiR-133 in
Heart and Skeletal Muscle
(A) Targets of miR-1 and processes they regulate
are shown.
(B) Targets of miR-133 and processes they regu-
late are shown.
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Studies in embryonic stem (ES) cells have revealed functions
for miR-1 and miR-133 in specification of mesodermal cell
fates. miR-1 and miR-133 are not expressed in undifferentiated
ES cells and are upregulated in early precardiac mesoderm
(Ivey et al., 2008). These two miRNAs function in concert to
promote mesoderm differentiation in ES cells, while suppressing
differentiation into the endodermal or neuroectodermal line-
ages (Ivey et al., 2008). Remarkably, reintroduction of miR-1
into SRF null ES cells restores mesodermal gene expression,
suggesting that the early functions of SRF in mesodermal line-
ages are mediated by the regulation of miR-1/133 expression
(Ivey et al., 2008).
In contrast to their parallel roles in repressing nonmuscle line-
ages, miR-1 and miR-133 have antagonistic effects on further
differentiation of muscle lineages: miR-1 promotes differentia-
tion of ES cells toward a cardiac fate, whereas miR-133 inhibits
differentiation into cardiac muscle (Ivey et al., 2008). miR-1 has514 Developmental Cell 18, April 20, 2010 ª2010 Elsevier Inc.been proposed to exert its effects by tar-
geting the Notch ligand Delta-like (Dll-1)
(Ivey et al., 2008) (Figure 4). The levels of
miR-1 and miR-133 also increase during
spontaneous myocardial differentiation
in ES cells in 2D culture (Takaya et al.,
2009). However, in this setting, forced
expression of miR-1 and miR-133 was
reported to suppress expression of car-
diac genes (Takaya et al., 2009). The
discrepancy between these findings in
terms of miR-1 function may be attribut-
able to the differences in cell-cell interac-
tions under different culture conditions.
Nonetheless, these studies clearly dem-
onstrate the importance of miR-1 and
miR-133 in regulating cardiac cell fates
during ES cell differentiation.
In Drosophila, miR-1 is also expressed
in early mesoderm. Mutations in the
miR-1 gene cause a spectrum of defects
in muscle differentiation ranging from
embryonic death to later demise in the
larval stages after hatching (Kwon et al.,
2005; Sokol and Ambros, 2005). In a
subset of miR-1 mutant flies, muscle
progenitors are arrested in a prolifera-
tive state and accumulate ectopically,
implicating miR-1 in regulating the deci-
sion to proliferate versus differentiate
(Kwon et al., 2005). As in mammalian
mesodermal progenitors, regulation of
the Notch ligand Delta by miR-1may contribute to the actions of this miRNA on Drosophila
cardiogenesis.
Control of Cardiac Growth and Development by miR-1
miR-1 and miR-133a regulate fundamental aspects of heart
development in vivo (Figure 4). Overexpression of miR-1 in the
embryonic heart under the control of b-MHC promoter inhibits
cardiomyocyte proliferation and causes lethality at E13.5 due
to a deficiency of cardiomyocytes (Zhao et al., 2005). Inhibition
of cardiac growth by miR-1 was proposed to be mediated by
translational inhibition of HAND2, a bHLH transcription factor
required for right ventricular growth (Srivastava et al., 1995;
Srivastava et al., 1997; Zhao et al., 2005). Although miR-1 and
Hand are conserved from flies to mammals, miR-1 does not
target Hand in flies, suggesting that the miR-1:Hand regulatory
link appeared later in evolution.
Targeted deletion of miR-1-2 in mice causes lethality with
incomplete penetrance between late embryogenesis and birth,
Table 1. Cardiovascular Phenotypes of miRNA Mutant Mice
miRNA Phenotype Reference
miR-1-2 50% viable; 50% w/ VSDs in embryos, and 50% w/ arrhythmias
and ecotpic cardiomyocyte proliferation in surviving adults, 15%
w/ cardiac dilation, ventricular dysfunction, and death
Zhao et al., 2007
miR-126 60% viable; 40% w/ lethal embryonic and perinatal hemorrhages Wang et al., 2008
Kuhnert et al., 2008
miR-133a-1 no apparent phenotype Liu et al., 2008
miR-133a-2 no apparent phenotype Liu et al., 2008
miR-133a dKO 56% w/ lethal VSDs at P1; 24% viable, with disrupted sarcomeres,
ectopic cardiomyocyte proliferation, and smooth muscle gene expression
Liu et al., 2008
miR-143 no apparent phenotype Xin et al., 2009
miR-145 reduced blood pressure, resistance to vascular stenosis Xin et al., 2009
miR-143/145 dKO similar to miR-145 KO Xin et al., 2009
Boettger et al., 2009
Elia et al., 2009
miR-208a viable; block to stress-dependent cardiac remodeling, reduced
slow/increased fast muscle gene expression; cardiac conduction defects
van Rooij et al., 2007
Callis et al., 2009
miR-208b viable, no apparent phenotype van Rooij et al., 2009
miR-499 viable, no apparent phenotype van Rooij et al., 2009
miR-208b/499 dKO viable; reduced slow/increased fast muscle gene expression van Rooij et al., 2009
miR-1792 perinatal lethality w/ VSDs Ventura et al., 2008
miR-106a363 viable, no apparent phenotype Ventura et al., 2008
miR-106b25 viable, no apparent phenotype Ventura et al., 2008
miR-1792/106b25 dKO embryonic lethality w/ VSDs, ASDs, thin myocardium Ventura et al., 2008
miR-1792/106a363/
106b25 tKO
same as dKO Ventura et al., 2008
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(Table 1). Consistent with the proposed role of miR-1 as a nega-
tive regulator of myocyte proliferation via HAND2,miR-1-2-defi-
cient mice display an increase in HAND2 expression and an
increased number of proliferating cardiomyocytes (Zhao et al.,
2007). Because miR-1-2 null mice express miR-1-1 at normal
levels, an understanding of the complete function of miR-1 in
cardiogenesis awaits the compound deletion of both miR-1-1
and miR-1-2 genes in mice. However, the fact that only a 50%
reduction in the overall level of miR-1 expression in these mice
results in such profound cardiac abnormalities underscores the
importance of the precise dosage of this miRNA for normal
cardiac development and function.Control of Cardiac Rhythm and Remodeling by miR-1
miR-1 modulates numerous ion channels involved in cardiac
conduction. In rats subjected to myocardial infarction (MI), over-
expression of miR-1 increased the occurrence of arrhythmias
(Yang et al., 2007). Delivery of an antisense oligonucleotide
against miR-1 in the rat infarct model reversed the predisposition
to arrhythmias. miR-1 was shown to regulate cardiac electro-
physiology by regulating the cardiac gap junction protein con-
nexin 43 and the potassium channel subunit Kir2.1 (Yang et al.,
2007). Consistent with these findings, miR-1-2 null mice exhibit
a spectrum of conduction abnormalities, including a shortened
PR interval and a prolonged QRS complex, which cause sudden
death (Zhao et al., 2007). Elevated levels of the transcription
factor Irx5, another target of miR-1 and a regulator of cardiacconduction channels, may also contribute to cardiac arrhyth-
mias in miR-1-2 null mice (Zhao et al., 2007).
miR-1 is downregulated in several models of cardiac hyper-
trophy and heart failure (Care` et al., 2007; Ikeda et al., 2009;
Sayed et al., 2007) and attenuates cardiomyocyte hypertrophy
when overexpressed in cultured cardiomyocytes and in adult
heart (Ikeda et al., 2009). This function of miR-1 has been attrib-
uted to the inhibition of MEF2A (Ikeda et al., 2009), a transcrip-
tional mediator of pathological cardiac remodeling (Potthoff
and Olson, 2007). miR-1 also inhibits calmodulin expression
and downregulates the calmodulin-calcineurin-NFAT signaling
pathway (Ikeda et al., 2009), which activates MEF2 and pro-
motes cardiac growth (Crabtree and Olson, 2002).Control of Cardiac Growth andDevelopment bymiR-133
Unlike the sensitivity of the heart to haploinsufficiency of miR-1
expression, mice lacking either miR-133a-1 or miR-133a-2
genes do not display obvious cardiac abnormalities, whereas
deletion of both genes results in late embryonic and neonatal
lethality due to VSDs and chamber dilatation (Liu et al., 2008)
(Table 1). The small subset of miR-133a-1/133a-2 double
knockout (dKO) mice that survives to adulthood develops dilated
cardiomyopathy and heart failure (Liu et al., 2008). miR-133a
null mice exhibit excessive proliferation and apoptosis of
cardiomyocytes, sarcomere disarray, and cardiac fibrosis (Liu
et al., 2008). Consistent with the enhanced proliferation of cardi-
omyocytes in mutant mice, several genes involved in cell cycle
control such as cyclins D1, D2, and B1 are upregulated inDevelopmental Cell 18, April 20, 2010 ª2010 Elsevier Inc. 515
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target of miR-133a (Liu et al., 2008). Conversely, overexpression
of miR-133a under the control of the b-MHC promoter inhibits
cardiomyocyte proliferation in the heart, which results in embry-
onic lethality due to thinning of ventricular walls and VSDs (Liu
et al., 2008). These consequences of overexpression comple-
ment the loss-of-function data to demonstrate that miR-133a
inhibits cardiomyocyte proliferation in the developing heart.
miR-133a null mice also display ectopic activation of smooth
muscle genes in the developing heart (Liu et al., 2008). During
normal heart development, smooth muscle genes are transiently
expressed at the heart tube stage (Li et al., 1996; McHugh, 1995;
Ruzicka and Schwartz, 1988). The aberrant expression of
smooth muscle genes in these mutant mice suggests therefore
that miR-133a null hearts are less mature than wild-type hearts.
miR-133a represses smooth muscle gene expression in the
heart by directly targeting several smooth muscle mRNAs, as
well as SRF, a regulator of smooth muscle gene expression
(Liu et al., 2008). The genetic interaction between miR-133a
and SRF creates a negative feedback loop in which the upregu-
lation of miR-133a by SRF results in increased repression of SRF
(Figure 2B).
miR-133a is downregulated in ventricular tissue of mice during
hypertrophy and various heart diseases (van Rooij et al., 2006;
Care` et al., 2007; Duisters et al., 2009). Accordingly, overexpres-
sion ofmiR-133a in cultured cardiomyocytes blunts hypertrophic
responses to agonist treatment (Care` et al., 2007). Delivery of an
antagomiR that blocks activity of miR-133awas shown to induce
cardiac hypertrophy in mice, which was mediated by derepres-
sion of the Ras homology gene family member A (RhoA) and
cell division cycle 42 (Cdc42) (Care` et al., 2007). In contrast,
miR-133a dKO mice develop dilated cardiomyopathy before
succumbing to heart failure and sudden death, without evidence
of cardiac hypertrophy (Liu et al., 2008). Several possibilities may
explain the different consequences of miR-133a inhibition by
antagomiRs versus genetic deletion. Because antagomiRs do
not completely eliminate the target miRNAs, in contrast to
genetic deletion, residual levels of miR-133a might be sufficient
for certain functions. In addition, genetic deletion eliminates
miRNA expression throughout the life of the organism, which
might allow for compensatory pathways that are not operative
during transient antagomiR-based knockdown.
miR-133a has been proposed to inhibit apoptosis by targeting
caspase 9 in cultured cardiomyocytes (Figure 4) (Xu et al., 2007).
Interestingly, however, caspase 9 protein levels were unaffected
in hearts of miR-133a dKO mice despite increased apoptosis of
cardiomyocytes (Liu et al., 2008). miR-133a regulates structural
changes in the extracellular matrix of the myocardium by target-
ing a profibrotic factor, connective tissue growth factor (CTGF)
(Duisters et al., 2009). miR-133a has also been implicated in
metabolic control of cardiomyocytes by targeting kruppel-like
factor 15 (KLF15), thus repressing expression of GLUT4, a glu-
cose transporter important for myocardial energy supply (Horie
et al., 2009). miR-133a also represses a potassium channel
gene HERG, contributing to QT prolongation and the associated
arrhythmias in diabetic rabbit hearts (Xiao et al., 2007), and has
been implicated in atrial fibrillation (Shan et al., 2009). In addition,
miR-133a regulates alternative splicing during myoblast differ-
entiation by regulation of the alternative splicing factor nPTB516 Developmental Cell 18, April 20, 2010 ª2010 Elsevier Inc.(Boutz et al., 2007). It is worth noting that most of the above
conclusions are based on overexpression of miR-133a, and
only a handful of genes shown to be targeted by miR-133a
in vitro are affected in miR-133a dKO mice. For example, the
surviving adult miR-133a dKO mice do not exhibit defects in
cardiac conduction or HERG expression.
The abnormalities in cardiac structure in miR-1-2 and miR-
133amutant mice are similar to those described in mice lacking
the miR-1792 cluster (also known as Oncomir-1), which gives
rise to a precursor trancript encoding six miRNAs that can be
grouped into four classes based on their seed sequence
(Ventura et al., 2008). Mice homozygous for a deletion of this
miRNA cluster die perinatally and show VSDs (Ventura et al.,
2008) (Table 1). miRNAs encoded by the miR-1792 cluster
are thought to promote cell survival by inhibiting expression of
the proapoptotic protein Bim1 (Ventura et al., 2008). Deletion of
two related miRNA clusters, miR-106b25 or miR-106a363,
has no effect on heart development, but combining either of
these null alleles with themiR-1792 null allele results in embry-
onic lethality accompanied by severe VSDs, ASDs, and thin-
walled myocardium (Ventura et al., 2008). Together, these stud-
ies of miR-1-2, miR-133a, and miR-1792 demonstrate how
relatively subtle changes in cardiac gene expression resulting
frommiRNA deletion can severely perturb cardiac development,
causing VSDs, which are the most common form of congenital
heart disease in humans (Hoffman and Kaplan, 2002).
Functions of miR-1 and miR-133 in Zebrafish
Experimental and computational studies in zebrafish point out
key functions of both miR-1 and miR-133 in shaping muscle
gene expression and regulating sarcomeric actin structure.
miR-1/206 and miR-133 are the two miRNAs with the strongest
influence on gene expression in embryonic muscle (Mishima
et al., 2009). More than half of the muscle mRNAs upregulated
in zebrafish embryos mutant for maternal and zygotic Dicer
function are predicted targets of miR-1 and miR-133 (Mishima
et al., 2009). miR-1 and miR-133 targets are enriched for actin
binding and vesicle transport functions, and interfering with the
function of these miRNAs disrupts sarcomeric organization of
actin in fast skeletal muscle.
miR-133 is highly expressed in adult caudal fin andwas shown
to negatively regulate fin regeneration in zebrafish (Yin et al.,
2008). FGF signaling, a critical pathway in regeneration, down-
regulates miR-133 during regenerative outgrowth. Forced ex-
pression of miR-133 attenuates fin regeneration, whereas
antagonism of miR-133 is sufficient to partially rescue fin regen-
eration that has been inhibited by FGF receptor blockade (Yin
et al., 2008). The Mps1 kinase, a positive regulator of blastemal
proliferation, is a target of miR-133 such that the absence of
miR-133 would be predicted to potentiate signaling through
this regenerative pathway. Whether miR-133a plays a role in
heart regeneration in zebrafish or other organisms remains to
be addressed.
A Family of miRNAs Encoded by Myosin Genes
Cardiac muscle contraction depends on the expression of two
MHC proteins, a-MHC (Myh6) and b-MHC (Myh7). In rodents,
a-MHC, a fast ATPase, is the predominant myosin isoform in
the adult heart, whereas b-MHC, a slow ATPase, is highly
Figure 5. Functions of MyomiRs in Cardiac and Skeletal Muscle
MyomiRs are encoded by myosin heavy chain (MHC) genes. Targets of MyomiRs and processes they regulate are shown.
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birth (Morkin, 2000). Cardiac stress and hypothyroidism result
in a switch in myosin content (Gupta, 2007; Krenz and Robbins,
2004), upregulating b-MHC and downregulating a-MHC, which
has profound effects on cardiac contractility and function.
b-MHC shares extensive homology with an ancient myosin,
Myh7b, the function of which is unknown (McGuigan et al., 2004).
These three muscle-specific myosin genes (Myh6, Myh7, and
Myh7b) encode a family of intronic miRNAs (miR-208a, miR-
208b, andmiR-499), calledMyomiRs, which control pathological
cardiac remodeling, muscle myosin content, myofiber identity,
and muscle performance (Figure 5) (Callis et al., 2009; van Rooij
et al., 2007, 2009).
miR-208a, the sole heart-specificmiRNA, is encoded by intron
29 of the a-MHC gene (Figure 5) (van Rooij et al., 2007). Similarly,
the b-MHC gene coexpresses a closely related miRNA, miR-
208b (Callis et al., 2009; van Rooij et al., 2009). miR-208a and
miR-208b have the same seed sequence and differ at only three
nucleotides in the 30 region. A third member of the MyomiR
family, miR-499, is encoded by intron 19 of the mouse Myh7b
gene (Rossi et al., 2009; van Rooij et al., 2008a, 2009). Although
the sequence of miR-499 differs substantially from miR-208a
and miR-208b, the seed region contains six overlapping bases,
implying that these miRNAs share overlapping functions and
regulate similar sets of targets. The MyomiRs are conserved
from fish to humans, but do not exist in invertebrates; their
appearance in evolution correlates with the diversification of
different myosin isoforms and the acquisition of stress- and
thyroid hormone (T3)-responsiveness of muscle, two key
gene programs that they regulate. Interestingly, the MyomiR
sequences are the only conserved intronic sequences in these
myosin genes, indicating that there was strong selection pres-
sure to maintain these sequences through evolution.
Expression of the MyomiRs parallels the expression of their
host genes during development and in response to stress and
T3 signaling. Like their host genes, miR-208a is highly expressedin adult mouse heart, whereas miR-208b is abundant in embry-
onic heart but is expressed at a low level in adult heart (Callis
et al., 2009; van Rooij et al., 2006, 2009). Myh7b and miR-499
are constitutively expressed at a high level in the heart (van Rooij
et al., 2009). While miR-208a is only expressed in the heart, both
miR-208b and miR-499 are also expressed in slow skeletal
muscles. In response to cardiac stress such as pressure over-
load, b-MHC/miR-208b is upregulated in the adult heart (Callis
et al., 2009; van Rooij et al., 2009). T3 signaling induces
a-MHC/miR-208a, whereas hypothyroidism results in a dramatic
increase in b-MHC/miR-208b expression (Callis et al., 2009; van
Rooij et al., 2009). Inhibition of T3 signaling also upregulates the
expression of Myh7b/miR-499 (van Rooij et al., 2009).
Control of Myosin Expression and Muscle
Performance by MyomiRs
MyomiRs play central roles in the regulation of the a-MHC to
b-MHC switch and in other aspects of the stress response and
T3 sensitivity of the heart (Figure 5). Mice lacking miR-208a are
viable but are resistant to fibrosis and cardiomyocyte hyper-
trophy in response to stress (Callis et al., 2009; van Rooij et al.,
2007). This function of miR-208a is mediated by repression of
T3 receptor coregulator 1 (THRAP1), an activator or repressor
of the T3 receptor, and myostatin, a repressor of hypertrophic
growth of both skeletal and cardiac muscles (Callis et al.,
2009; Cook et al., 2002; Ito and Roeder, 2001; Lee, 2004; van
Rooij et al., 2007). Most notably, miR-208 null mice fail to upre-
gulate b-MHC in response to stress and inhibition of T3 signaling
in the adult heart. In addition, fast skeletal muscle genes are
inappropriately expressed in miR-208a null hearts (van Rooij
et al., 2007) (Table 1).
miR-208a controls not only the expression of b-MHC/miR-
208b in response to stress and hypothyroidism, but also the
expression of Myh7b/miR-499 in the adult heart. Both Myh7b
and miR-499 are completely absent in adult hearts of the
miR-208a null mice (van Rooij et al., 2009). Overexpression ofDevelopmental Cell 18, April 20, 2010 ª2010 Elsevier Inc. 517
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reactivate the expression of b-MHC/miR-208b and to repress
ectopic expression of fast muscle genes, suggesting that miR-
499 is a downstream mediator of miR-208a actions (van Rooij
et al., 2009). Overexpression of miR-499 inmiR-208a null hearts
also reactivates the expression of Myh7b, which suggests the
existence of a positive autoregulatory loop whereby miR-208a
regulates Myh7b and its intronic miRNA, miR-499, which regu-
lates b-MHC (van Rooij et al., 2009) (Figure 4).
Defects in cardiac conduction have also been reported in
miR-208a null mice. miR-208a is likely to control cardiac con-
duction by regulating expression levels of the gap junction pro-
tein connexin 40 and the homeodomain-only protein (Hop) and
GATA4 transcription factors (Callis et al., 2009) (Figure 5).
Consistent with these findings, mice overexpressing miR-208a
develop cardiac hypertrophy and arrhythmias (Callis et al.,
2009).
In addition to their functions in the heart, MyomiRs also control
themyofiber gene program in skeletal muscle (Figure 5). Gain-of-
function and loss-of-function analyses demonstrated that
miR-208b andmiR-499 redundantly specify muscle fiber identity
by activating slow and repressing fast myofiber genes (van Rooij
et al., 2009). The actions of MyomiRs in skeletal muscle are
mediated by a collection of transcriptional repressors of slow
muscle genes, including Sox6, Purb, and Sp3, which are all
repressors of b-MHC expression, and HP-1b, a repressor of
MEF2 (van Rooij et al., 2009).
Taken together, these studies demonstrate that MyomiRs,
which are embedded in myosin genes, in turn regulate myosin
gene expression and muscle identity in response to physiolog-
ical and pathological signaling. The incorporation of MyomiRs
into the introns of myosin genes that they regulate provides an
efficient means of ensuring coregulation of the miRNA and the
gene program under its control, rather than creating separate
sets of cis-regulatory elements to control expression of the
miRNA and the myosin gene. Intriguingly, the regulatory circuitry
among MyomiRs and their host genes is only seen in the adult
heart and not in the fetal heart, because b-MHC/miR-208b and
Myh7b/miR-499 are expressed normally in neonatal hearts of
miR-208a null mice (van Rooij et al., 2009).
Control of Cardiac Patterning by miR-138
Zebrafish have a two-chambered heart containing a single
atrium and ventricle separated by the atrioventricular canal
(AVC) (Stainier, 2001). miR-138 is specifically expressed in the
ventricular chamber of the zebrafish heart. Knockdown of miR-
138 by morpholino and antagomiR in zebrafish embryos led to
expansion of AVC gene expression into the ventricular chamber
and failure of ventricular cardiomyocytes to fully mature, indi-
cating that miR-138 is required for cardiac maturation and
patterning in zebrafish (Morton et al., 2008). It is worth noting
that the requirement of miR-138 during cardiac development is
limited only to a distinct temporal window of early cardiac loop-
ing, and miR-138 was dispensable thereafter (Morton et al.,
2008). miR-138 restricts AVC gene expression in the ventricle
by negatively regulating the cell adhesion molecule versican
and repressing the retinoic acid signaling pathway (Morton
et al., 2008). It will be interesting to study whether other miRNAs
have functions similar to miR-1380s in ‘‘clearing’’ unwanted518 Developmental Cell 18, April 20, 2010 ª2010 Elsevier Inc.mRNA expression from a specific region of the heart, thus estab-
lishing cardiac patterning. miR-138 is conserved from zebrafish
to humans, so it will also be interesting to determine whether
it plays similar roles in patterning of the mammalian four-cham-
bered heart.
Control of Vascular Development and Stress
Responsiveness by miR-143 and miR-145
In addition to regulation of cardiomyocyte development and
function, recent reports have revealed roles of miRNAs in
vascular development. Smooth muscle cells (SMCs) are highly
plastic and possess the ability to modulate their phenotypes
between differentiated, proliferative, or migratory states in
response to vascular injury or growth factor signaling. This plas-
ticity contributes to a variety of vascular disorders including
atherosclerosis, restenosis following angioplasty, and hyperten-
sion (Owens et al., 2004). The cardiovascular-specific miRNAs,
miR-143 and miR-145, play key roles in modulating vascular
SMC (VSMC) phenotypes.
Regulation of miR-143/145 Expression during
Cardiovascular Development
miR-143 and miR-145 have distinct sequences, but are
transcribed as a bicistronic unit. The miR-143/145 cluster is
expressed in cardiac progenitors in the cardiac crescent as early
as E7.5 and throughout the developing heart until E16.5, as well
as in the dorsal aorta and other developing vessels (Boettger
et al., 2009; Cordes et al., 2009; Xin et al., 2009). In adult
mice, expression is restricted to vascular and visceral SMCs.
Independent studies from two groups have revealed a single
SRF binding site (CArG box) in the enhancer region that is
required for expression in SMCs (Cordes et al., 2009; Xin et al.,
2009). However, conflicting results were obtained in terms of
whether SRF also controls cardiac expression. Xin et al. reported
that mutations in the single CArG box eliminated both cardiac
and smooth muscle expression in embryos, thus making SRF
and its coactivators Myocardin/MRTF-A solely responsible for
both cardiac and SMC expression of miR-143/145. However,
Cordes et al. reported that cardiac expression depends on an
evolutionarily conserved binding site for Nkx2.5. Although the
basis for these differing results is unclear, in SRF null embryonic
heart at E9.5, expression of miR-143 is significantly downregu-
lated, supporting the role of SRF in controlling cardiac expres-
sion of the miR-143/145 gene (Niu et al., 2008).
Control of Smooth Muscle Fate by miR-143/145
miR-143 and miR-145 are downregulated in injured and athero-
sclerotic vessels and in cultured dedifferentiated VSMCs (Cheng
et al., 2009; Cordes et al., 2009; Elia et al., 2009). VSMC differen-
tiation genes are upregulated by overexpression of miR-145
and downregulated by inhibition of miR-145 in cultured VSMCs
(Cheng et al., 2009). Restoration of miR-145 expression in
balloon-injured arteries inhibits neointimal growth (Cheng et al.,
2009). These studies demonstrated that miR-145 promotes
VSMC differentiation and represses proliferation in response to
vascular injury, thus making miR-145 a novel modulator of
VSMC plasticity.
Work by Cordes et al. has provided intriguing insights into the
roles of miR-143 and miR-145 in controlling VSMC cell fate.
Figure 6. Model for the Regulation of
Smooth Muscle Phenotypes and Actin
Dynamics by miR-143 and miR-145
miR-143 andmiR-145 are cotranscribedas abicis-
tronic unit. The targets of these miRNAs and the
processes they regulate are shown.
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cells was sufficient to drive these multipotent cells into function-
ally mature VSMCs (Cordes et al., 2009). miR-145 can also
robustly potentiate myocardin-dependent conversion of fibro-
blasts into VSMCs. The SRF coactivator myocardin is a master
regulator of SMC fate, and it is sufficient to reprogram fibroblast
cells into VSMCs (Pipes et al., 2006; Wang et al., 2003). Although
neither miR-143 nor miR-145 alone was sufficient to reprogram
fibroblasts, overexpression of miR-145 in the presence of myo-
cardin robustly enhances the conversion of fibroblasts into
VSMCs, and inhibition of miR-145 blocks myocardin-dependent
conversion (Cordes et al., 2009). Thus, miR-145 is apparently
required for myocardin activity in reprogramming fibroblasts.
Especially striking is the finding that miR-145 directly targets
Myocardin by enhancing rather than decreasing its expression
(Cordes et al., 2009). This stimulatory effect is mediated
by a miR-145 target sequence in the 30 UTR of the Myocardin
mRNA. Themechanistic basis for the dramatic stimulatory effect
of miR-145 on myocardin translation remains to be defined.
These findings are in contrast to the generally accepted inhibi-
tory roles of miRs on protein expression. In addition to targeting
myocardin, miR-145 represses expression of Klf4 and calmod-
ulin kinase II-delta (CamkIId), both of which positively regulate
SMC proliferation (Cordes et al., 2009). miR-143, on the other
hand, directly represses translation of Elk1, a myocardin com-
petitor and an activator of VSMC proliferation (Cordes et al.,
2009; Wang et al., 2004). Based on these results, a model has
been proposed in which miR-145 and miR-143 modulate coac-
tivator and corepressor activity of SRF to promote differentiation
and repress proliferation of VSMCs (Figure 6). In addition to
controlling VSMC differentiation in vitro, miR-145 was shownDevelopmental Cellto silence the self-renewal program of
human ES cells by directly repressing
the core pluripotency factors Oct4,
Sox2, and Klf4, thus facilitating ES cell
differentiation (Xu et al., 2009).
Control of Stress-Dependent
Vascular Remodeling
by miR-143/145
One major question from in vitro cell
culture studies is whether miR-145 and
miR-143 control VSMC and ES cell differ-
entiation in vivo. In particular, is miR-145
required for myocardin activity on VSMC
differentiation or stem cell pluripotency
in vivo as reported in vitro? If miR-145
indeed is required for myocardin function,
one might expect genetic deletion of
miR-145 in mice to cause phenotypes
similar to those of myocardin null mice,whichdie at E10.5due to a failure in VSMCdifferentiation (Li et al.,
2003). On the contrary, mice homozygous for miR-143/145
deletion are viable without obvious abnormalities during early
embryogenesis (Boettger et al., 2009; Elia et al., 2009; Xin
et al., 2009) (Table 1). Thus, neither miR-143 nor miR-145 is
essential for VSMC differentiation in vivo, which is in contrast
to their reported functions in vitro. Perhaps compensatory
mechanisms in vivo override the requirement of miR-143 and/
or miR-145 in VSMC differentiation.
In spite of the dispensable roles of miR-143 and miR-145
during embryogenesis, mice lacking these miRNAs exhibit
smooth muscle abnormalities, including thinning of the muscular
wall of the aorta and other arteries and a shift fromadifferentiated
toward a synthetic phenotype (Boettger et al., 2009; Elia et al.,
2009; Xin et al., 2009). Correspondingly, the contractility of
arteries is compromised, accompanied by reduced expression
of a subset of differentiated VSMC markers and an increase in
synthetic VSMC markers. These smooth muscle defects can
be attributed, at least in part, to abnormalities in actin dynamics
and cytoskeletal assembly (Xin et al., 2009). The number and
prominence of actin stress fibers in VSMCs of mice lacking
miR-145 and miR-143 are significantly reduced. Whether the
thinner smooth muscle layers of the aorta are due to defects in
differentiation of the neural-crest-derived SMC lineage during
development remains to be determined. Mice lacking miR-145
also display reduced blood pressure (Boettger et al., 2009; Elia
et al., 2009; Xin et al., 2009). Especially intriguing is the finding
that neointima formation in response to carotid artery ligation
is profoundly impeded in mice lacking miR-145, or both miR-
143 andmiR-145. The dKOmice also develop neointimal lesions
in the femoral arteries at 18 months of age (Boettger et al., 2009).18, April 20, 2010 ª2010 Elsevier Inc. 519
Figure 7. Model for miR-126 Function in
Endothelial Cells
miR-126 is encoded by an intron of the Egfl7 gene.
Targets of miR-126 and the processes they regu-
late are shown.
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the regulation of SRF activity and actin dynamics, thus creating
a complex set of feedback loops to modulate cytoskeletal
assembly and dynamics (Xin et al., 2009). An unbiased
genomic/proteomic analysis allowed identification of other
miR-143/145 targets involved in contractility of VSMCs, such
as angiotensin-converting enzyme (ACE) (Boettger et al.,
2009). Knockdown of miR-145 in zebrafish results in defects in
gut smooth muscle and epithelium maturation, which have
been ascribed to dysregulation of GATA6 (Zeng et al., 2009).
Together, the in vivo studies of miR-143 and miR-145 have
demonstrated that these two miRNAs function in multiple path-
ways to control VSMC phenotypes and actin remodeling
(Figure 6). Despite being expressed at high levels in the devel-
oping heart, no cardiac function of miR-143 or miR-145 has yet
been found.
It is puzzling that transient overexpression of miR-145 in vitro
or in the vessel wall in vivo blocks SMC growth and promotes
differentiation, while genetic deletion of miR-145 in mice also
appears to block vascular growth in response to mechanical
injury. How might these seemingly contradictory findings be
reconciled? One explanation is that transient overexpression
assays reveal a subset of potential miRNA functions resulting
from acute modulation of downstream targets in response to
nonphysiological levels of miRNA expression, whereas genetic
deletion of miRNAs in vivo reveals the function of the miRNA in
the setting of persistent deletion and associated compensatory
mechanisms that do not exist in short-term overexpression
studies. In addition, there is precedent in other systems for over-
expression and knockdown of miRNAs having similar conse-
quences, which likely reflects their roles in buffering fluctuations
in gene expression such that tilting the balance of a particular
target one way or the other perturbs that process (Choi et al.,
2007).
Control of Angiogenesis by miR-126
Endothelial cells (ECs) form the internal surfaces of the vascula-
ture and are essential for vascular development and disease
(Carmeliet, 2003). Mounting evidence indicates that miRNAs
are important regulators of vascular development and angiogen-
esis. Mice with EC-specific deletion of Dicer display defects in520 Developmental Cell 18, April 20, 2010 ª2010 Elsevier Inc.postnatal angiogenesis (Sua´rez et al.,
2008). Numerous miRNAs have also
been shown to regulate tumor angiogen-
esis in vitro and in vivo, such as miR-378,
miR-296, and the miR-1792 cluster
(Dews et al., 2006; Lee et al., 2007; Wu¨r-
dinger et al., 2008).
The EC-specific miR-126 is encoded
by an intron of the EGF-like domain 7
(Egfl7) gene, which encodes a growth
factor involved in cell migration. EC-spe-cific expression of Egfl7/miR-126 is controlled by Ets transcrip-
tion factors (Wang et al., 2008). Deletion of miR-126 in mice
causes leaky vessels, hemorrhaging, and partial embryonic
lethality (Kuhnert et al., 2008; Wang et al., 2008). Similarly,
knockdown of miR-126 in zebrafish results in loss of vascular
integrity and hemorrhage during embryonic development (Fish
et al., 2008). Surviving miR-126 null mice display defects in
cardiac neovascularization following MI, resulting in cardiac
rupture and death.miR-126 null ECs are also defective in angio-
genesis in response to angiogenic factors (Wang et al., 2008).
Recently, knockdown of miR-126 with an antagomiR has been
shown to inhibit the ischemia-induced angiogenic response
(van Solingen et al., 2009). The proangiogenic actions of
miR-126 have been ascribed to the negative regulation of the
Sprouty-related protein 1 (Spred1) and phosphatidylinositol
3-kinase p85beta (PIK3R2), negative regulators of the MAP
kinase and the PI3 kinase signaling pathways, respectively
(Fish et al., 2008; Wang et al., 2008) (Figure 7). miR-126 also
plays a role in vascular inflammation by targeting vascular cell
adhesion molecule 1 (VCAM-1) (Schmidt et al., 2007) (Figure 7).
In addition, miR-126 is downregulated in many cancer lines and
inhibits tumorigenesis by targeting CT10 regulator of kinase
(CRK), PIK3R2, insulin receptor substrate-1 (IRS-1), and other
genes (Crawford et al., 2008; Guo et al., 2008; Tavazoie et al.,
2008; Zhang et al., 2008) (Figure 7). Interestingly, a recent report
showed that miR-126 inhibits proliferation of nonsmall cell lung
cancer (NSCLC) cells by positively regulating expression of its
host gene, Egfl7 (Sun et al., 2010).
In miR-126 null mice, expression of the host gene Egfl7 is not
changed at the mRNA or protein level (Wang et al., 2008). Inter-
estingly, miR-126 null mice have similar vascular abnormalities
to those ofmicewith a targeted deletion of the Egfl7 gene, raising
the question of whether the phenotype of this strain of Egfl7 null
mice is attributable to loss of miR-126 function (Schmidt et al.,
2007). Indeed, another recently generated strain of Egfl7 null
mice, in which miR-126 expression is unaffected, is phenotypi-
cally normal (Kuhnert et al., 2008), suggesting that the vascular
abnormalities of the former strain of Egfl7 null mice are attribut-
able to the deletion ofmiR-126. This finding highlights the possi-
bility that other gene deletions in mice may have inadvertently
deleted miRNAs embedded in introns of protein-coding genes,
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embedded miRNA. Evaluation of intronic miRNAs should there-
fore be a general consideration in the design of gene targeting
strategies.
Recently, miR-92a, another EC-specificmiRNA, was shown to
control angiogenesis and functional recovery of damaged
tissues after MI (Bonauer et al., 2009). Numerous other miRNAs
have been shown to play key roles in tumor angiogenesis (Wang
and Olson, 2009), but their potential functions in blood vessel
development during embryogenesis and cardiovascular devel-
opment have not yet been explored.
miRNAs as Modifiers of Stress Responses
and Heart Disease
Even though we provide examples of miRNAs that play key roles
in numerous facets of heart development and disease, many
other miRNAs can be deleted in the heart with relatively minimal
consequences on cardiac development. This observation sug-
gests that subtle changes in gene expression (<2-fold) resulting
from miRNA deletion can be tolerated in vivo (at least in a
controlled setting) without perturbing tissue homeostasis. Simi-
larly, there are numerous cases in Drosophila and C. elegans
in which miRNA deletion evokes minimal phenotypes (Li and
Carthew, 2005; Li et al., 2006; Miska et al., 2007), yet many
miRNAs are evolutionarily conserved, indicative of important
functions. In contrast, there are now numerous examples, partic-
ularly in the heart, in which the absence of specific miRNAs
results in a pronounced response to stress—either exacerbating
the consequences of the insult or protecting the heart from injury
(van Rooij and Olson, 2007).
Howmight the absence of phenotypes of miRNAmutant mice,
and the manifestation of phenotypes in response to stress, be
explained? One explanation for such tolerance is the phenom-
enon of network buffering, in which multiple, compensatory
regulatory interactions buffer the effects of loosing one node in
a complex web of regulatory interactions (Bartel, 2009), whereas
under conditions of injury or stress, there may be heightened
requirements for precise protein levels to maintain normal func-
tions of a regulatory network. Stress is also likely to alter multiple
nodes within a regulatory network such that compensatory inter-
actions are diminished. Another explanation for the lack of devel-
opmental phenotypes in miRNA knockout mice is that most
mRNAs are targeted by multiple unrelated miRNAs such that
many miRNAs need to be disrupted before the depression of
a specific mRNA has perceptible consequences.
Although miRNA gene deletions in mice have relatively minor
consequences in the absence of stress, and only in the case of
miR-1 has a 50% reduction of a cardiac miRNA been shown to
cause lethality (Zhao et al., 2007), haploinsufficiency in humans
is the basis for numerous diseases, particularly in the heart,
underscoring the potential impact of relatively subtle changes
in protein dosage on heart development and function (Garg,
2006; Mori and Bruneau, 2004; Yamagishi, 2002). miRNAs may
therefore exert stronger effects in humans than in animal models.
In this regard, a hallmark of congenital heart disease in humans is
variable penetrancy and expressivity, pointing to the existence of
modifiers of cardiac phenotypes. Whether mutations in miRNAs
or their target sites may cause heart disease in humans by either
disrupting or creating miRNA:mRNA interactions remains to bedetermined. It is intriguing that a single nucleotide polymorphism
in the 30 UTR of the mRNA encodingMyostatin, a member of the
TGF-b family and negative regulator of muscle growth, has been
shown to cause dramatic muscle hypertrophy in the Texel
strain of sheep (Clop et al., 2006). This mutation creates a target
sequence for miR-1, causing repression of myostatin expression
and unrestrained muscle growth as seen in mice with Myostatin
loss-of-function mutations (Clop et al., 2006). Although human
polymorphisms that influence miRNA target sites and contribute
to disease have also been described, genetic and functional
evidence for the causality of these polymorphisms in disease is
lacking (Sethupathy and Collins, 2008).
The VSDs and ASDs in mice lacking miR-1, miR-133a, and
miR-1792 suggest the potential involvement of these and other
miRNAs in congenital heart disease. It is intriguing in this regard
that DiGeorge syndrome, which is associated with cardiac
abnormalities, is caused by a deletion of a region of chromosome
22 that encodes DGCR8, a component of the pri-miRNA pro-
cessing complex (Gregory et al., 2004; Han et al., 2004). The fact
that this syndrome results from haploinsufficiency of this locus
raises the possibility that perturbation of miRNA expression
could contribute to the gene dosage sensitivity of this disease
by impacting numerous miRNA targets.
The seemingly minimal effects of miRNAs on unstressed
adult tissues and their selective contributions to remodeling
responses of diseased tissues make miRNAs attractive targets
for therapeutic manipulation because strategies to inactivate
disease-inducing miRNAs might have modest off-target effects
on normal tissues. Therapeutic manipulation of miRNA levels in
the heart represents a promising approach for the modification
of disease phenotypes. In this regard, modulators of miRNAs,
such as antagomiRs and miR mimics, have shown promising
effects on a number of cardiovascular disorders in animal
models (Bonauer et al., 2009; Care` et al., 2007; Thum et al.,
2008). Moreover, the sophisticated approaches for catheter-
based delivery to the heart should facilitate the introduction of
miRNA-based therapeutics directly to sites of cardiac injury,
bypassing possible off-target effects on other tissues (van Rooij
et al., 2008b). It is also likely that miRNAs will have diagnostic or
prognostic applications for heart disease.
Signature patterns of miRNAs have been identified in a variety
of cardiac disorders (e.g., hypertrophy, heart failure, ischemic
cardiomyopathy, post-MI remodeling) (Ikeda et al., 2007; Sayed
et al., 2007; Tatsuguchi et al., 2007; Thum et al., 2007; van Rooij
et al., 2006, 2008c), and recent studies have reported miRNAs in
the blood and the elevation of specific miRNAs following MI
(Laterza et al., 2009).
Concluding Remarks
Despite current insights into the roles of miRNAs in heart devel-
opment and disease, our understanding of howmiRNAs function
is far from complete, and numerous conceptual and experi-
mental questions remain. To date, only a handful of the hundreds
of miRNAs expressed in the cardiovascular system have been
functionally analyzed. Identification of additional miRNAs and
analyses of the functions of their targets promise to provide
new and unanticipated insights into mechanisms of cardiovas-
cular development, function, and dysfunction. The realization
that miRNAs play central roles in modulation of congenital andDevelopmental Cell 18, April 20, 2010 ª2010 Elsevier Inc. 521
Developmental Cell
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vides a new perspective on these disorders and has revealed
unanticipated cellular mechanisms of disease and potential
new therapeutic targets. Finally, the functions of miRNAs in heart
development and disease are undoubtedly representative of the
roles of these regulatory RNAs in other tissues. Thus, we antici-
pate further lessons from the heart.
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